Future-proof your AAV process with a complete producer cell line – just induce and grow
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Stable producer cell lines helped to make mAb therapies the powerhouses that they are today. To deliver on the promise of AAV-based gene therapy for prevalent diseases, similar technology is required. The challenge is that multiple genetic elements – rep, helper, capsid, and gene of interest (GOI) – must be present. Ideally, everything needed to produce the required rAAV would be stably integrated into a single cell line.
In this webinar, we describe an all-inclusive cell line platform that can be customized for your specific GOI and capsid. Just add the induction agent, and you’re ready to go.
- Discover the drawbacks of using an incomplete cell line
- See how to use the ELEVECTA™ platform to produce high-quality AAV at high yield for indications with large patient populations
- Take a deep dive into data on robust scaling to large-scale stirred tank bioreactors
- Learn how to optimize your upstream processing with cells, media, bioreactors, and filters that work in tandem
SPEAKERS
You might also like
Control your AAV titers with in-line UV-Vis analysis and PAT-Driven UF/DF systems
It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
Accelerating AAV process development with PAT-driven TFF system
